Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway

Why It Matters

The setback removes a potential revenue stream for Insmed while accelerating competitors' dominance in the growing hidradenitis market. It also refocuses Insmed on capitalizing on Brinsupri's strong lung‑disease sales momentum.

Key Takeaways

• CEDAR Phase 2b showed placebo outperformed Brinsupri doses.
• Insmed will abandon hidradenitis suppurativa program for Brinsupri.
• Incyte, UCB, Novartis report recent successes in hidradenitis.
• Brinsupri posted $144.6 million Q4 2025 sales after approval.

Pulse Analysis

Insmed's decision to halt Brinsupri's skin‑disease development underscores the challenges of repurposing drugs without robust pre‑clinical data. The CEDAR Phase 2b trial revealed that both 10‑mg and 40‑mg doses failed to reduce abscess and inflammatory nodule counts, with placebo delivering a 57.1% reduction versus 45.5% and 40.3% for the active arms. Analysts had already assigned a low 10% success probability, citing weak animal models and an unclear mechanism for hidradenitis suppurativa. This outcome forces Insmed to concentrate resources on its flagship indication—non‑cystic fibrosis bronchiectasis—where Brinsupri has already demonstrated market traction.

The hidradenitis suppurativa market is rapidly consolidating around a few biologics that have secured FDA approvals and strong clinical data. Incyte's JAK1 inhibitor povorcitinib showed sustained benefit over 54 weeks in two Phase 3 trials, while UCB's dual IL‑17A/IL‑17F blocker Bimzelx received approval in November 2024 and has now demonstrated three‑year durability. Novartis expanded its Cosentyx label to include pediatric patients, reinforcing its position as a market leader. These successes create a high barrier for new entrants, especially oral small molecules lacking clear efficacy signals, and suggest that future competition will likely come from next‑generation biologics or novel mechanisms.

Financially, Insmed's lung‑disease franchise remains a bright spot. Brinsupri generated $144.6 million in fourth‑quarter 2025 sales, exceeding forecasts and establishing the drug as the first approved treatment for bronchiectasis. By shedding the underperforming skin program, the company can allocate capital toward expanding Brinsupri's indication portfolio, enhancing manufacturing capacity, and pursuing strategic partnerships. Investors will watch how Insmed leverages this cash flow to sustain growth while navigating a competitive landscape that increasingly favors biologics in dermatology.